Kory James Wentworth is CFO at Entrada Therapeutics, Inc. (TRDA). They have made 11 open-market trades across 2 companies since 2018, most recently 2026-09-02.
CIK 0001725663
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TRDA | 117,277 | $513K |
| BLUE | 9,512 | $47K |
| Total | $560K |
Shares reported on the most recent Form 4, priced at the 2026-09-03 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TRDA | SELL · 10b5-1 | 2026-04-01 | 2026-04-02 | $12.95 | $32K | +5.1% | +18.8% | -42.9% |
| TRDA | SELL | 2026-03-09 | 2026-03-11 | $13.01 | $214K | -14.4% | +0.6% | -52.6% |
| TRDA | SELL | 2026-03-04 | 2026-03-06 | $12.25 | $98K | -4.0% | +12.1% | -43.6% |
| TRDA | SELL · 10b5-1 | 2025-11-21 | 2025-11-24 | $9.98 | $178K | +1.7% | +4.2% | +11.2% |
| TRDA | SELL · 10b5-1 | 2025-03-17 | 2025-03-19 | $10.67 | $19K | -14.6% | -24.9% | -31.9% |
| TRDA | SELL · 10b5-1 | 2024-11-29 | 2024-12-03 | $20.00 | $120K | -12.5% | -13.5% | -43.9% |
| TRDA | SELL · 10b5-1 | 2024-11-11 | 2024-11-13 | $19.98 | $345K | -4.2% | -11.2% | -38.4% |
| TRDA | SELL · 10b5-1 | 2024-09-09 | 2024-09-10 | $14.97 | $48K | -0.3% | +7.4% | +46.2% |
| TRDA | SELL · 10b5-1 | 2024-07-08 | 2024-07-10 | $14.95 | $26K | +7.0% | -12.3% | +2.5% |
| TRDA | SELL · 10b5-1 | 2024-03-06 | 2024-03-08 | $12.31 | $101K | +5.1% | +5.9% | +24.4% |
| TRDA | SELL · 10b5-1 | 2023-12-21 | 2023-12-26 | $15.63 | $355K | -5.8% | -11.2% | -20.2% |
| TRDA | SELL · 10b5-1 | 2023-09-06 | 2023-09-06 | $13.48 | $13K | +2.9% | +6.7% | +0.9% |
| TRDA | SELL · 10b5-1 | 2023-07-10 | 2023-07-12 | $17.98 | $290K | +6.9% | +3.5% | -1.5% |
| TRDA | SELL · 10b5-1 | 2023-06-21 | 2023-06-23 | $15.01 | $525K | +8.9% | +15.5% | -7.2% |
| TRDA | SELL · 10b5-1 | 2023-03-02 | 2023-03-03 | $10.52 | $18K | +25.4% | +40.0% | +5.4% |
| TRDA | SELL | 2022-12-08 | 2022-12-12 | $18.95 | $172K | -7.6% | -17.6% | -21.5% |
| TRDA | SELL | 2022-12-02 | 2022-12-06 | $18.19 | $57K | +25.8% | -16.8% | -37.7% |
| TRDA | SELL · 10b5-1 | 2022-11-16 | 2022-11-18 | $18.10 | $4K | -2.2% | +10.1% | -47.0% |
| TRDA | SELL · 10b5-1 | 2022-08-24 | 2022-08-26 | $13.79 | $64K | +6.1% | +5.5% | +5.0% |
| TRDA | SELL | 2022-08-19 | 2022-08-23 | $13.08 | $264K | +1.7% | +3.5% | +11.2% |
| TRDA | SELL · 10b5-1 | 2022-08-16 | 2022-08-18 | $13.02 | $8K | -10.0% | +5.6% | +35.0% |
| BLUE | SELL · 10b5-1 | 2020-08-03 | 2020-08-05 | $61.00 | $5K | -1.5% | -10.9% | -13.7% |
| BLUE | SELL · 10b5-1 | 2020-07-20 | 2020-07-22 | $66.38 | $40K | -3.9% | -9.8% | -15.8% |
| BLUE | SELL | 2020-06-04 | 2020-06-08 | $65.23 | $10K | -6.4% | -3.1% | -17.7% |
| BLUE | SELL | 2020-01-07 | 2020-01-09 | $89.97 | $20K | +2.9% | -0.6% | -52.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.